21 Jun [MCE]: High-throughput Screening Accelerates Drug Combination Therapy
Drug combination therapy provides a viable and promising way to overcome drug resistance in cancer treatment. Recent advances in automation and data analysis, increasing availabilities of compound libraries and better understanding of disease mechanisms have made high throughput screening a powerful tool to accelerate the development of drug combination therapy. Cumulative results, such as the AstraZeneca’s drug combination data set of the DREAM challenge and DrugComb, show that bioactive compounds, especially FDA-approved compounds and compounds being tested in clinical trials, are frequently used for combination screening because of their relatively clear biological activity and overall offer a high success rate of drug repurposing.
As a global supplier of high-quality bioactive compounds and compound libraries, MCE provides 30,000+ bioactive compounds and more than 100 compound libraries.
MCE compound libraries will accelerate your drug combination study. The following compound libraries are recommended for drug combination research:
| Cat. No. | Library Name | Description | |
| HY-L035 | Drug Repurposing Compound Library | 3,800+ approved drugs and passed phase I clinical compounds with well-characterized bioactivities, safety and bioavailability properties. | |
| HY-L022 | FDA-Approved Drug Library | 2,600+ approved drugs with clear bioactive information and indications. | |
| HY-L026 | Clinical Compound Library | 1,900+ compounds studied in clinical trials. All compounds are supplied with detailed information on clinical development status, research area, targets, etc. | |
| HY-L001 | Bioactive Compound Library | 15,000+ compounds with confirmed biological activities and clear targets. |
Products are for research use only and are not intended for human use. We do not sell to patients.
Request Your Quote